expressed Interferon Stimulated Genes that mediate antiviral innate immunity. Previous studies 23 have revealed that most IFITs partake in higher order structures, potentially as part of an 'IFIT 24 interactome' that results in viral inhibition. Recent crystal structures of a mutated, monomeric form 25 of IFIT1 revealed the molecular basis of how it recognizes non-self, capped viral mRNAs to 26 selectively inhibit their translation. However, wild-type IFIT1 forms dimers in solution and the 27 role of dimerization was not examined in detail. Here we present a structural and biochemical 28 analysis of wild-type IFIT1 in complex with capped and uncapped RNA. Wild-type IFIT1 forms 29 an antiparallel, elongated dimer that is in stark contrast to the domain-swapped, parallel dimer 30 found in IFIT2. Dimerization takes place through a small, C-terminal interface that is 31 evolutionarily conserved in IFIT1 and IFIT1B proteins. The interface is modular and can be grafted 32 onto IFIT5, which is natively monomeric, to induce dimerization. Mutational analysis of this 33 interface showed that homo-dimerization is not required for full RNA binding IFITs are cytosolic proteins composed of multiple tandem copies of the tetratricopeptide repeat 47 chains from the two co-crystal structures yields backbone root mean square deviations (r.m.s.d.) 144 of 0.2-0.5 Å for all C ! atoms, indicating minimal differences between the two molecules of the 145 ASU or between the different RNA-bound forms (Fig. S3A) . 146 We also determined a high resolution, 1.58 Å structure of an RNA-bound, monomeric 147 variant of IFIT1, generated with the aid of the IFIT1 dimer structure determined here (discussed 148 below). The structure of each molecule of IFIT1 from the wild-type dimer form is similar to the 149 monomeric variant, except for small changes at flexible regions and near the protein C-terminus 150 that are likely due to differences in crystal packing (Fig. S3, B and C) . The details of IFIT1-RNA 151 binding have already been described in an earlier study (6), and here we focus mainly on the 152 mechanism of dimerization and conformational changes associated with RNA binding. 153
Overall structure of the RNA-bound human IFIT1 dimer 154
The two molecules of the ASU interact in a tail-to-tail manner exclusively through their C-terminal 155 regions to form a near two-fold symmetric, S-shaped dimer with ~173° rotation between them and 156 approximate dimensions of 140 Å x 80 Å x 50 Å ( Fig. 2A) . Each monomer of IFIT1 is composed 157 of 23 !-helices, 18 originating from its 9 TPR motifs, organized into 3 distinct subdomains (Fig.  158 2A). As with IFIT5, the subdomains come together to form a positively-charged RNA binding 159 tunnel at the core of the protein, which in IFIT1 encircles the cap and four RNA nucleotides ( Fig.  160 2, A, B and C) giving rise to the preference for binding only ssRNA with unstructured 5´ ends or 161 dsRNA with 5´ overhangs (5, 6, 23). The m7G moiety of the cap sits at one end of the tunnel inside 162 a relatively hydrophobic cap-binding pocket between subdomains I and II ( Fig. 2A, B and D) . The 163 m7G electron density in the 2.8 Å model is not well defined (Fig. S2) , consistent with the presence 164 of two base conformations (syn and anti) observed in the 1.58 Å structure of monomeric IFIT1 165 with m7Gppp-RNA (6). As before, one side of the m7G base interacts with Trp 147 (through π-π 166 stacking) and Ile 183, while the other contacts Leu 46 and Thr 48 from a 'cap-binding loop' (Fig.  167   2D) . 168
The RNA-binding tunnel continues along the central super-helix of the protein, spanning 169 subdomain II (TPR3-TPR6), the pivot region (!15+!16), and the N-terminal portion of subdomain 170 III (TPR7-TPR8) ( Fig. 2A) . The 3´ end of the RNA (N4) emerges from the tunnel and points 171 towards a positively-charged, solvent exposed groove which may contribute to non-specific RNA 172 binding ( Fig. 2C) (6) . As with IFIT5, !21 intervenes between TPR8 and TPR9 to cap the central 173 super-helix and alter the right-handed super-helical trajectory at the end of each molecule (Fig.  174   2A) . TPR9, in turn, mediates IFIT1 dimerization. The overall arrangement of IFIT1 dimers thus 175 positions the two RNA-binding tunnels in a roughly antiparallel fashion with respect to one 176 another, and results in two non-contiguous RNA-binding surfaces (Fig. 2, A and C) . 177
The elongated IFIT1 dimer is distinct from that of IFIT2 (44 % sequence identity), which 178 forms a parallel side-to-side dimer through N-terminal domain swapping ( (Fig. S4A) , which improves to 0.44-1.1 Å when only subdomains I, II, or III are 181 used in the superposition (Fig. S4B) . 182
Mechanism of IFIT1 dimerization 183
TPR motifs are generally composed of a degenerate, 34 amino-acid sequence that folds into a pair 184 of antiparallel helices (helices A and B) (4). Tandemly arranged TPR motifs will then assemble 185 into super-helical arrays through conserved hydrophobic interactions between helices A and B 186 within one motif, and between one TPR and helix A´ of the following motif. In this manner, the 187 minimal building block for a TPR array is 1.5 TPR motifs (or AB-A´), and the repeating pattern 188 (i.e. AB-A´B´-A´´B´´) continues until the array is capped at its end by an A-like helix. When 189 present at the C-terminus of a protein, this capping helix also functions as a 'solubility helix'. For 190 example, in IFIT5, the very C-terminal helix !24 follows TPR9 to bury its hydrophobic surface 191 and prevent further extension of the super-helix (Fig. 3A) . In comparison, IFIT1 is prematurely 192 truncated because it lacks a corresponding helix !24 (Fig. 3A and 4A) . The resulting exposedhydrophobic surface on TPR9 is instead capped by an opposing TPR9 from another molecule, thus 194 forming a tail-to-tail elongated dimer. 195
The dimer interface buries ~ 530 Å 2 of surface area (determined by PISA, (29)) and is 196 composed of several small and large hydrophobic residues, including Leu 457, Tyr 460, and Leu 197 464 from each TPR9 motif (Fig. 3, B, C and D) . The interface is further stabilized by reciprocal 198 hydrogen bonds between Tyr 460 and Glu 461, and salt bridges between Lys 448 and Glu 461 199 (Fig. 3B) . The residues involved in dimerization are conserved across mammalian IFIT1 genes, 200
indicating an evolutionarily conserved mechanism for dimerization (Fig. 4, A and B) . The 201 interface is also conserved in IFIT1B proteins, suggesting that they use the same mechanism of 202 homo-dimerization. 203
Mutational analysis of dimerization 204
The above described dimer is but one of several distinct dimerization interfaces in the crystal 205 lattice. To confirm that the IFIT1 dimerization observed in our solution experiments is the one 206 mediated by its C-terminus and not one of the other crystal packing interfaces, we performed a 207 mutational analysis of TPR9 which we assayed by analytical gel filtration (Fig. 5A) DM-A , and IFIT1 DM-E revealed no discernable differences (Fig. S5B) . Additionally, 219 the crystal structure of RNA-bound IFIT1
DM-E described in our previous analysis of IFIT1-RNA 220 interactions revealed no major differences between the wild-type and mutant protein (Fig. S3B) . 221
To determine if TPR9 alone is responsible for dimerization, we created a chimera of human 222 IFIT5 !1-!21 (residues 1-435) and human IFIT1 !22-!23 (TPR9, residues 437-478). Analytical 223 gel filtration showed that the chimera can form homo-dimers in solution (Fig. 5B) , and electro-224 mobility gel shift assays (EMSAs) between the chimera and a 42-nucleotide RNA (GGG42) shows 225 that it retains binding to PPP-RNA (Fig. 5C) . However, PPP-RNA binding by the chimera is 226 weaker compared to IFIT5, possibly because dimerization interferes with the dynamics of IFIT5 227 closure around the RNA. Taken together, the mutational analysis confirms the role of TPR9 and 228 its hydrophobic surface in mediating IFIT1 dimerization, and shows that this motif can behave as 229 an independent dimerization module. 230
IFIT1 dimers form a pseudo-continuous TPR super-helix 231
The central portion of IFIT1 dimers (TPR9s and several preceding helices) where they associate 232 bears a striking resemblance to small TPR domains such as the synthetic TPR protein, cTPR3 (4), 233 made up of three idealized motifs (Fig. 6A) . In fact, the residues involved in IFIT1 dimerization 234 from the second helix of TPR9 are highly conserved when compared to consensus TPR motif 235 sequences derived from a large database of TPR containing proteins (Fig. 6C ) (4). These residues 236 are usually critical for mediating the intra-molecular TPR stacking interactions that give rise to 237 continuous TPR arrays (Fig. 6B) . Interestingly, however, there is one key difference between the 238 inter-molecular stack at the IFIT1 C-terminus and canonical intra-molecular TPR stacking. 239
Whereas canonical TPR stacking is between one TPR and helix A of the next, in IFIT1 the inter-240 molecular stacking is between TPR9 and helix B of the adjoining TPR9 instead of another A-like 241 helix (Fig. 6, A and B) . Thus, the two TPR9 motifs of each IFIT1 molecule interact in a mannerthat is analogous to intra-molecular TPR stacking, and form a pseudo-continuous TPR super-helix 243 which is responsible for IFIT1 dimerization. 244
IFIT1 dimerization is dispensable for full RNA binding and inhibition of translation 245
To investigate the role of dimerization in RNA binding by IFIT1, we performed an EMSA utilizing 246 a 43-nucleotide m7Gppp-RNA with a five-residue overhang at the 5´ end, which is optimal for 247 IFIT1 binding (6). The capped RNA was fluorescently labelled at the 3´ end with pCp-Cy5, and 248 binding to wild-type IFIT1 and the monomeric mutant IFIT1
DM-E was tested (Fig. 7A) . Both 249 proteins bound the capped RNA with the same apparent affinity of ~ 50-100 nM, suggesting that 250 dimerization is not required for optimal RNA binding. Moreover, SYBR-Gold stained EMSAs 251 with other unlabeled m7Gppp-RNAs, including two virus derived sequences, showed similar 252 results ( Fig. S6) . 253 We next looked at the impact of dimerization on IFIT1 translational inhibition. To address 254 this, we utilized an in vitro translation system consisting of Krebs extracts programmed with a 255 bicistronic mRNA reporter ( Titrating IFIT1 or IFIT1
DM-E into the extracts at concentrations of 30 nM to 5 µM resulted in 260 similar reductions of FF levels (compared to buffer control) (Fig. 7C) . In both cases, Ren levels 261 only dropped by 5-10 % indicating minimal non-specific activity. Thus, IFIT1 and IFIT1
DM-E exert 262 similar translation inhibition, confirming that homo-dimerization is not required for IFIT1 263 inhibitory activity in an in vitro setting. 264
RNA binding is associated with large-scale conformational changes 265
The means by which RNA gains entry to its binding site in IFIT1 is not immediately apparent, 266 particularly because of the narrow shape and depth of the tunnel. To gain insight into the RNAdependent conformational changes, we performed limited protease digestion of IFIT1 with trypsin 268 and endoproteinase Glu-C, which revealed that both PPP-oligoA-and capped-oligoA-bound IFIT1 269 exhibit a greater degree of stabilization than RNA-free IFIT1 (Fig. 8A) . The capped-RNA bound 270 complex was more resistant to proteolysis than PPP-RNA-bound IFIT1, which reflects either 271 specific conformational changes associated with capped-RNA binding or, more likely, the stronger 272 affinity of IFIT1 towards capped-RNA (6, 22). 273
The two major stable fragments resulting from endoproteinase Glu-C treatment of IFIT1 274 without RNA have apparent MWs of ~ 35 and ~ 32 kDa (Fig. 8A, bottom) . We further examined 275 these using in-gel tryptic digestion followed by LC/MS/MS, which showed that both originate 276 from the protein N-terminus, namely subdomains I and II ( corresponds to the elastase-resistant fragment of human IFIT1 previously crystallized (Fig. 8B) . 279
When Glu-C cleavage was repeated in 0.1 M ammonium bicarbonate buffer, we observed slower 280 kinetics of degradation, which we took advantage of to follow the IFIT1/Glu-C degradation profile 281 over a period of 17 hours (Fig. 8C) . Given that mRNA likely enters the tunnel from the C-terminal side of the protein, it is unclear how 289 the m7G moiety is accommodated inside the cap-binding pocket, which forms a narrow, circular 290 extension at the N-terminal side of the tunnel (Fig. 2B) . To address this, we compared the 291 structures of PPP-RNA-bound and m7Gppp-RNA-bound IFIT1, which revealed small-scale 292 conformational within the cap-binding loop (residues 45-50). This loop forms one wall of the cap-293 binding pocket and is stabilized by binding of the m7G moiety, as it is somewhat disordered in the 294 PPP-RNA structure (Fig. 8, D and E) . However, based on crystal temperature factors it seems that 295 the loop retains its dynamic nature even in the presence of the cap (Fig. S8A) . In the crystal 296 structure of RNA-free, N-terminal IFIT1 (composed of SD I+II (5)), the cap-binding loop also 297 appears to be mobile as it has high temperature factors (Fig. S8B) . Interestingly, these small-scale 298 conformational changes were not evident from the high-resolution structures of the monomeric 299
IFIT1
DM-E bound to PPP-and m7Gppp-RNA, since the cap-binding pocket of its PPP-RNA bound 300 form was occupied by PEG molecules from the crystallization solution, artificially stabilizing the 301 cap-binding loop (6). Nevertheless, the plasticity of the cap-binding loop is likely to be an 302 important element in m7G recognition, as it would facilitate mRNA binding by leaving the cap-303 binding pocket in a more open and accessible state (Fig. 8E) . On the other hand, the critical cap-304 binding residue Trp 147 is coordinated by Glu 176 in all structures, and appears to form a pre-305 organized 'landing pad' for m7G binding (Fig. 2D) . Supporting the importance of the W147-E176 306 interaction for IFIT1 function, disrupting this coordinating pair through mutation (W147F or 307 E176A) reduced binding to capped-RNA and translational inhibitory activity (6). 308
Discussion

309
The Interferon-Induced Proteins with Tetratricopeptide Repeats family has been reported to 310 mediate their antiviral effects through various mechanisms (31). Central to this ability is the TPR 311 motif, a versatile protein-protein interaction module which in IFITs has also adapted to interact 312 with virus-derived RNA (5, 6, 32). One facet of IFIT antiviral activity is the formation of an IFN-313 dependent, multi-protein complex with IFIT1, IFIT2, and IFIT3 at its core (19). The mechanisms 314 regulating homo-and hetero-oligomerization of the IFIT core of this complex remain poorly 315 characterized. The crystal structure of IFIT2 showed that it homo-dimerizes via domain swapping 316 in which the N-terminal portion of its subdomain II (helices !7-!9) is exchanged between the 317 interacting IFIT2 molecules (8). We report here the structural basis for IFIT1 dimerization, which 318 utilizes a different mechanism for self-association. IFIT1 dimerizes through the formation of a C-319 terminal, pseudo-continuous TPR super-helix, which forms in a manner that mimics naturally 320 occurring, intra-molecular TPR-stacking interactions that normally give rise to continuous TPR 321 arrays. 322 TPR containing proteins have been shown to assemble into homo-dimers and higher order 323 complexes using diverse mechanisms, ranging from those which resemble TPR-peptide 324
interactions (e.g. the self-assembling, magnetosome-forming MamA (33)), to interactions which 325 involve entire TPR domains encircling each other and burying up to 6000 Å 2 (e.g. subunits of the 326 anaphase-promoting complex (34)). The crystal structure of an engineered TPR domain made up 327 of consensus motifs (CTPR3Y3) has been shown to assemble into trimers with one interface 328 forming a C-terminal pseudo-continuous super-helix (35), similar to IFIT1. As with IFIT1, the 329 pseudo-continuous super-helix of CTPR3Y3 involves displacement of a C-terminal capping helix, 330 except in IFIT1 this capping helix appears to be lost due to a C-terminal truncation (when 331 compared to IFIT5). Nevertheless, our structure confirms the notion that displacement or loss of a 332 capping-helix giving rise to pseudo-continuous TPR arrays may be a general mechanism for TPR 333 protein oligomerization (35). We propose that TPR9 can be used as a TPR dimerization module to 334 facilitate the design of self-assembling TPR molecules. We demonstrated the feasibility of this by 335 grafting the IFIT1 TPR9 sequence onto human IFIT5, thereby converting it from a monomer to a 336 dimer. 337 TPR proteins have also been reported to form crystallographic dimers that wouldn't 338 otherwise form in solution (36), but we thoroughly validated the presence of IFIT1 dimerization 339 in solution using gel-filtration, SEC-MALS, and AUC. These data are consistent with the 340 formation of IFIT1 oligomers during RNA-binding gel shift assays and during protein blue-native 341 PAGE electrophoresis (22). Additionally, human and rabbit IFIT1 were shown to bind cappedRNA with low-level positive cooperativity (Hill coefficient, n = 1.6-1.7) (22). However, co-343 immunoprecipitation assays failed to detect an IFIT1 self-interaction in human cells (19), possibly 344 because the interaction is relatively weak. This is supported by our AUC analysis where we 345 observed that wild-type IFIT1 had established a rapidly reversible monomer-dimer equilibrium 346 during centrifugation. Furthermore, the relatively small dimerization interface burying only ~ 530 347 Å 2 is smaller than expected for a stable self-interaction (37) 
Experimental Procedures 408
Plasmids-IFIT1, IFIT2, and IFIT5 were sub-cloned into pSMT3 between BamHI and NotI sites, 409 resulting in a fusion protein with an N-terminal, Ulp1-cleavable 6xHis-Sumo tag (40). IFIT1 point 410 mutants were generated by site-directed mutagenesis using iProof High-Fidelity DNA polymerase 411 (Bio-Rad). The chimera made up of IFIT5 (residues 1-435) and IFIT1 (residues 437-478) was 412 generated using overlap-extension PCR, and sub-cloned into pSMT3 between BamHI and NotI. 413
Expression and purification of IFIT proteins-IFIT1, IFIT1 mutants and IFIT5 expression and 414 purification are described elsewhere (6). The IFIT5/IFIT1 chimera was expressed in Rosetta 2 415 (DE3) pLysS BL21 cells (Novagen) by first growing transformed cells in LB at 37 °C until an 416 OD 600 of 0.6-0.8, followed by induction with 1 mM IPTG and growing the cells for 4 hours at 30°C . The protein was purified by Ni-affinity chromatography followed by cleavage of the tag. The 418 cleaved protein was further purified by passing over a 5 ml HiTrap SP HP column (GE Healthcare) 419 equilibrated with 50 mM HEPES pH 7.5 and 1 mM DTT, followed by washing with 50 mM 420 HEPES pH 7.5, 100 mM NaCl, and 1 mM DTT, and eluted with 50 mM HEPES pH 7.5, 400 mM 421 NaCl, and 1 mM DTT. IFIT2 was expressed in BL21 (DE3) and purified using 2-step Ni-affinity 422 chromatography (with cleavage of the tag) using standard protocols. All proteins were further 423 purified by gel filtration using superdex 200 10/300 or 16/60 columns (GE Healthcare) in 20 mM 424
Tris pH 7.6, 150 mM NaCl and 1 mM DTT. 425
Preparation of PPP and m7Gppp containing oligoadenylate RNA-PPP-AAAA and Gppp-AAAA 426 were prepared using phosphoramidite solid phase synthesis followed by installation of the 427 triphosphate or cap moieties as previously described (6); the oligos were purified by HPLC and 428 characterized by LC-MS as before (6). m7Gppp-AAAA was prepared by enzymatically modifying 429
Gppp-AAAA with purified mRNA cap guanine-N7 methyltransferase as before (6). All data were collected at 100K with 0.979 Å X-rays on beamline 08ID-1 at the CLS, which was 437 equipped with a Mar300CCD detector (41), and the images integrated, scaled, and merged using 438 the HKL2000 suite (43). Data were truncated with Ctruncate (ccp4 suite (42)) and 5 % of 439 reflections were set aside for the R free set. Only the highest resolution dataset was used as a master 440 file to generate all R free sets. Data collection statistics from HKL2000 are in Table S2 . Table S2 . 457
Sequence and structure analysis-APBS was used to calculate the surface electrostatic potential 458 (48), and PyMol to general all molecular figures (https://www.pymol.org/). For surface 459 electrostatic analysis, all surfaces are colored by electrostatic potential from negative (-10 kTe-1; 460 red) to positive (+10 kTe-1; blue). ESPript was used to generate the sequence alignment in Fig.  461 4A (49). Sequence conservation analysis by WebLogo (50) in Fig. 4B was performed as described 462
(6). 463
Analytical gel filtration-500 µL (Fig. 5A) or 250 µL (Fig. 5B) of purified protein at 2 mg/ml were 464 injected onto a superdex 200 10/300 increase column (GE Healthcare) equilibrated in 20 mM TrispH 7.6 and 150 mM NaCl. 1 µg (Fig. 5A) or 2 µg (Fig. 5B) 
RNA electro-mobility gel shift assays (EMSA)-Capped RNAs for EMSAs were prepared by in 502
vitro transcription with T7 RNA polymerase followed by PAGE purification and post-503 transcriptional capping with the vaccinia capping system (NEB) as previously described (6). 504
Preparation of pCp-labelled RNA was performed with T4 RNA ligase (NEB) as previously 505 described (6). Gel shifts were performed exactly as described before (6). 506
Circular dichroism (CD) spectroscopy-IFIT1, IFIT1
DM-A , or IFIT1 DM-E were buffer exchanged 507 into 50 mM Na 2 HPO 4 /NaH 2 PO 4 pH 8 and diluted to a final concentration of 0.5 508 mg/ml. Measurements were performed on a Chirascan CD spectrometer using a 0.2 mm quartz 509 cell. CD wavelength scans were obtained at 21 °C , with 1 nm step size and 0.5 s time intervals. 510
The signals obtained were in CD millidegrees and are represented as an average of three spectra 511 obtained for each sample. The averaged spectra were smoothened using the Savitsky-Golay 512 method and a window size of 3. 513 Table S1 . 
In vitro translation assay with Krebs extracts-
